Company profile
UK company 04336899, incorporated on 10 December 2001.
Drug Discovery Services | Enrich Your Medicines Pipeline | Domainex
Enrich your medicines pipeline - Domainex provides a complete range of preclinical drug discovery services tailored to meet all your research needs
Company number 04336899
Updated 07 Jul 2026 09:49
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
AD01 | Transaction MzU0NzU3MTI2MWFkaXF6a2N4
Published 25 Sep 2026 08:22
AA | Transaction MzU0NzM4Mjg0NGFkaXF6a2N4
Published 24 Sep 2026 11:44
SH10 | Transaction MzU0MTIzNjU5MmFkaXF6a2N4 | Paper/PDF filed
Published 09 Sep 2026 02:20
SH10 | Transaction MzU0MTIzNjU5M2FkaXF6a2N4 | Paper/PDF filed
Published 07 Sep 2026 09:30
SH10 | Transaction MzU0MTIzNjQ0NGFkaXF6a2N4 | Paper/PDF filed
Published 07 Sep 2026 09:29
RESOLUTIONS | Transaction WUY5QjZJS0FhZGlxemtjeA | Paper/PDF filed
Published 07 Sep 2026 09:28
MA | Transaction MzUzOTY5NzUwMGFkaXF6a2N4 | Paper/PDF filed
Published 01 Sep 2026 22:52
SH01 | Transaction MzUzOTY5ODc2N2FkaXF6a2N4
Published 19 Aug 2026 08:39
Company registered at Companies House
1 May 2018 to 30 Apr 2019
"G-protein coupled receptors (GPCRs) are proteins found on the surface of cells: they detect molecules outside the cell and consequently activate internal signalling pathways that mediate cellular responses. GPCRs are one of the most important human drug target classes, and are addressed by 25-30% of marketed drugs. Many GPCRs that are known to have disea...
1 Oct 2015 to 31 Dec 2016
Our aim is to establish the feasibility of finding a new treatment for cancer by targeting a family of three enzymes called the NSDs. Recent academic research has shown that in myeloma and some other types of cancer the NSD family can switch on the production of other proteins that help these cancers grow. This work leads us to believe that a drug which c...
1 Oct 2014 to 30 Sep 2017
This project aims to deliver an advanced candidate drug for the treatment for Chronic Obstructive Pulmonary Disease (sometimes refered to as emphysema or chronic bronchitis) – a highly debilitating condition that affects more than 200 million people worldwide and leads to over 6 million early deaths every year. The consequent social, economic, and health-...
1 Feb 2013 to 31 Jan 2014
Our aim is to establish the feasibility of a new treatment for cancer that works by targeting the enzyme SMYD3. Recent academic research has shown that SMYD3 is not present in normal cells, but in many cancer cells it switches on the production of other proteins that help tumours grow and spread throughout the body. So this work suggests that a drug that ...
1 Oct 2012 to 31 Jan 2014
This project aims to establish the feasibility of a new treatment for Chronic Obstructive Pulmonary Disease – a highly debilitating condition that affects more than 200 million people worldwide and leads to over 6 million early deaths every year. The consequent social, economic, and health-care burden is huge. Treatment for COPD usually involves relieving...
1 Nov 2011 to 31 Jan 2013
Our aim is to invent a new drug for the treatment of several common cancers through inhibition of the enzymes IKKe and/or TBK1. Recent academic research has shown that blocking these closely-related protein kinases will stop cancer cells growing, and force them to die. Furthermore these enzymes are important in some inflamatory diseases, obesity, and Type...
1 Aug 2010 to 31 Mar 2011
Awaiting Public Summary
